Aksu, GoncaDoğanlar, OğuzhanDoğanlar, Zeynep Banu2021-11-202021-11-2020202148-47242548-0030https://dergipark.org.tr/tr/pub/tmsj/issue/57652/819208https://dergipark.org.tr/tr/download/article-file/1373503https://hdl.handle.net/20.500.14551/6227Aims: The aim of this study is to carry out the effect of 5-Fluorouracil alone or combined with Ruxolitinib on both apoptosis and JAK/STAT pathway in U87 glioblastoma cells. Methods: We used U87 glioblastoma cell lines as the human brain cancer cells. We treated the cells with 5-Fluorouracil (3.125 ?M-400 ?M) alone and with a combination of Ruxolitinib (100 ?M or 400 ?M of Ruxolitinib with 3.125-25 ?M 5-Fluorouracil), and performed the MTT test for calculating IC50 value. Molecular fluorescence staining was performed with Hoechst and acridine orange/ethidium bromide probes. The alteration in mitochondrial apoptosis and JAK/STAT pathways to drug treatment was analyzed by the qRT-PCR assay. Results: Decrease in cell viability was more prominent in U87 cells treated with a combination of 5-Fluorouracil and Ruxolitinib compared to those treated with 5-Fluoro- uracil alone. In gene expression analysis, apoptosis signals were observed in cells treated with 5-Fluorouracil alone and 5-Fluo- rouracil+Ruxolitinib treatment. Conclusion: Treatment with 5-Fluorouracil alone and 5-Fluorouracil+Ruxolitinib combination increased apoptosis in U87 glioblastoma cells. However, it is difficult to mention an evident difference between treatments. Therefore, further studies are needed.eninfo:eu-repo/semantics/openAccess5-FluorouracilRuxolitinibglioblastomaapoptosisJAK/STAT pathwayArticle73130139819208